An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide – a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) – plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.